Astria Therapeutics Inc Stock Price, News & Analysis

Astria Therapeutics (NASDAQ: ATXS) has announced its upcoming presentation at the Eastern Allergy Conference in Palm Beach, Florida on May 30, 2025. Dr. Raffi Tachdjian from UCLA will present poster F40, highlighting attack severity reduction data from the ALPHA-STAR Phase 1b/2 trial of navenibart (STAR-0215) in patients with Hereditary Angioedema (HAE). The presentation will focus on how the treatment reduces attack severity and the need for rescue medication. The session is scheduled for 9:45am EST at The Breakers Palm Beach.

Astria Therapeutics (NASDAQ:ATXS) reported Q1 2025 financial results and provided updates on its key programs. The company's lead candidate navenibart is currently in the ALPHA-ORBIT Phase 3 trial for hereditary angioedema (HAE), with top-line results expected in early 2027. Previous Phase 1b/2 trial results showed 90-95% reduction in monthly attack rates. The company is also developing STAR-0310, a monoclonal antibody for atopic dermatitis, with Phase 1a results expected in Q3 2025.

Financial highlights for Q1 2025:

• Cash position: $295.1M (vs $328.1M in Q4 2024)
• Net loss: $33.7M ($0.58 per share)
• R&D expenses: $27.8M
• G&A expenses: $9.2M

The company expects current cash to fund operations into mid-2027, covering the completion of the ALPHA-ORBIT Phase 3 trial and STAR-0310 Phase 1a trial.

Astria Therapeutics (NASDAQ: ATXS) has granted stock options to three new employees under its 2022 Inducement Stock Incentive Plan. The options allow for the purchase of 33,650 shares of common stock at an exercise price of $5.16 per share, matching the closing price on May 1, 2025. These options will vest over four years, with 25% vesting after the first year and the remainder vesting monthly over the following 36 months. The grants, made in accordance with Nasdaq Listing Rule 5635(c)(4), are exclusively for new employees and are contingent upon continued employment with Astria.

Astria Therapeutics (NASDAQ: ATXS) has published Phase 1a trial results for navenibart, their potential treatment for hereditary angioedema (HAE), in the Annals of Allergy, Asthma & Immunology. The trial demonstrated promising results with navenibart showing a mean half-life of 82-105 days for doses ≥300 mg, supporting potential dosing intervals of every 3 and 6 months. The drug showed statistically significant inhibition of plasma kallikrein activity compared to placebo (P<0.05). Importantly, navenibart was well-tolerated with adverse event rates similar to placebo and no serious adverse events reported. These results support the ongoing pivotal Phase 3 trial called ALPHA-ORBIT and suggest navenibart's potential to become a first-choice therapy for HAE patients.

Astria Therapeutics, a biopharmaceutical company developing therapies for allergic and immunologic diseases, has announced an upcoming presentation at the Citizens Life Sciences Conference.

The company's CEO, Jill C. Milne, Ph.D., will participate in a fireside chat scheduled for Wednesday, May 7th at 10:30am ET. Investors and interested parties can access the presentation through a live webcast link, with an archived replay remaining available on the company's website for 30 days after the event.

The presentation represents an opportunity for investors to gain insights into Astria's developments in the immunologic disease treatment space. The company, trading under the Nasdaq symbol ATXS, continues to maintain transparency with its stakeholders through participation in key industry events.

Astria Therapeutics (NASDAQ:ATXS) has granted stock options to two new employees under its 2022 Inducement Stock Incentive Plan. The company awarded options to purchase 43,650 shares of common stock at an exercise price of $5.40 per share, matching the closing price on April 1, 2025.

The options will vest over a four-year period, with 25% vesting on the first employment anniversary and the remaining shares vesting monthly over the following 36 months, contingent on continued employment. These grants were made in accordance with Nasdaq Listing Rule 5635(c)(4) as inducement material for new hires.

Astria Therapeutics (NASDAQ:ATXS) reported its Q4 and full year 2024 financial results, highlighting significant progress in its clinical programs. The company initiated the ALPHA-ORBIT Phase 3 trial of navenibart for hereditary angioedema (HAE) in February 2025, with top-line results expected in early 2027.

Key financial metrics for 2024 include:

• Cash position of $328.1 million as of December 31, 2024
• Net loss of $94.3 million for full year 2024
• R&D expenses increased to $77.1 million
• G&A expenses rose to $34.5 million

The company expects its current cash position to fund operations into mid-2027. Phase 1b/2 ALPHA-STAR trial results showed 90-95% reduction in mean monthly attack rates. Additionally, Astria initiated a Phase 1a trial of STAR-0310 for atopic dermatitis, with initial results anticipated in Q3 2025.

Astria Therapeutics (ATXS), a biopharmaceutical company developing therapies for allergic and immunologic diseases, has granted stock options to five new employees under its 2022 Inducement Stock Incentive Plan. The options cover 87,450 shares of common stock with an exercise price of $6.10, matching the closing price on March 3, 2025.

The options will vest over four years, with 25% vesting on the first employment anniversary and the remainder vesting monthly over the following 36 months, contingent on continued employment. These grants were made in accordance with Nasdaq Listing Rule 5635(c)(4) as inducement for new hires.

Astria Therapeutics (NASDAQ: ATXS) has initiated the ALPHA-ORBIT Phase 3 pivotal trial of navenibart for hereditary angioedema (HAE). The global, randomized, double-blind, placebo-controlled study will evaluate the drug's efficacy and safety over 6 months in up to 135 adults and 10 adolescents with HAE Type 1 or 2.

The trial features three dosing arms for adults: 600mg followed by 300mg every 3 months (Q3M), 600mg every 6 months (Q6M), and 600mg Q3M, plus placebo. Adolescents will receive 600mg followed by 300mg Q3M. The primary endpoint is time-normalized monthly HAE attacks at 6 months.

The Phase 3 program design was based on positive Phase 1b/2 ALPHA-STAR trial results, which demonstrated 90-95% reduction in mean monthly attack rate and up to 67% attack-free rate over 6 months. Top-line results are expected in early 2027.